NASDAQ:IRD Opus Genetics Q4 2024 Earnings Report $5.41 -0.41 (-7.04%) Closing price 09/16/2026 04:00 PM EasternExtended Trading$5.52 +0.11 (+2.11%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$1.27Consensus EPS -$0.34Beat/MissMissed by -$0.93One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$3.40 millionExpected Revenue$11.10 millionBeat/MissMissed by -$7.70 millionYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterQ4 2024Date3/31/2025TimeBefore Market OpensConference Call DateMonday, March 31, 2025Conference Call Time7:00AM ETUpcoming EarningsOpus Genetics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Opus Genetics Earnings HeadlinesOpus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?September 16 at 8:30 PM | insidermonkey.comOpus Genetics consensus price target increased 21.47% to $12.98September 16 at 1:18 AM | msn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 17 at 1:00 AM | Profits Run (Ad)Wedbush Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) StockSeptember 12, 2026 | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Sees Unusually-High Trading Volume After Analyst UpgradeSeptember 12, 2026 | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Oppenheimer Analyst SaysSeptember 11, 2026 | americanbankingnews.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss or blindness. The company aims to address conditions for which treatment options are limited or unavailable by developing therapies designed to correct or replace disease-causing genetic defects in retinal cells. Opus Genetics’ pipeline includes investigational programs for genetically defined retinal disorders, including rhodopsin-associated autosomal dominant retinitis pigmentosa and BEST1-related retinal disease. Its programs are intended to use gene therapy approaches to deliver functional genetic material to affected retinal tissues. The company’s assets remain in the research and clinical-development stages and are not broadly marketed commercial products. Opus Genetics was established in 2021 and has pursued the development of treatments for rare ophthalmic diseases through internal research and collaborations. The company is headquartered in the United States and focuses primarily on advancing potential therapies through preclinical and clinical testing for patients with inherited retinal diseases.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big3 Luxury Consumer Brands to Watch in a Beaten-Down SectorJackson’s Record Quarter Powers the Bull CaseMarex Stock Doubles on Record Profits, But Can the Rally Continue?The Ultimate Cyber Shield: CrowdStrike Rises Past $2352 "Cheap for a Reason" Airline Stocks That May Be Worth the RiskMarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
